Silence Therapeutics (SLN) Payables (2018 - 2026)

Silence Therapeutics has reported Payables for 9 years, with the latest figure at $10.4 million in Q1 2026.

• Quarterly Payables fell 44.89% year-over-year to $10.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.4 million (down 44.89% YoY) and the FY2025 annual result came in at $13.4 million, down 18.56% from the prior year.
• Payables retreated to $10.4 million in Q1 2026 per SLN's latest filing, from $13.4 million in the prior quarter.
• Over five years, Payables peaked at $18.8 million in Q1 2025 and troughed at $10.4 million in Q1 2026.
• A 5-year average of $15.1 million and a median of $15.1 million in 2023 frame the typical range for Payables.
• The sharpest annual moves came in 2024 and 2026: Payables advanced 6.31% in 2024, then slumped 44.89% in 2026.
• Over 5 years, Payables stood at $14.8 million in 2022, then increased by 4.11% to $15.4 million in 2023, then advanced by 6.31% to $16.4 million in 2024, then declined by 18.56% to $13.4 million in 2025, then slipped by 22.38% to $10.4 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $10.4 million, $13.4 million, and $17.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.